Wrinkle Reduction Device Approved in USA
Apyx Medical Corporation (NASDAQ: APYX), the producer of Renuvion®, a proprietary helium plasma and radiofrequency technology, previously announced the receipt of 510(k) clearance from the United States Food and Drug Administration ("FDA") for the use of the Renuvion Dermal handpiece in specific dermatological procedures for the treatment of moderate to severe wrinkles and rhytides in patients with Fitzpatrick skin types I, II, or III.
This wrinkle-reduction treatment, marketed as Facial Renewal, offers patients a nonsurgical option for smoothing and contracting the skin in a single procedure. Dermatologists, plastic surgeons, and cosmetic physicians can achieve transformative results with Facial Renewal without invasive surgery or risking looking unnatural. Renuvion Facial Renewal is the first major advancement in decades of face skin treatments, providing patients with dramatic and natural-looking results.
"Renuvion for facial procedures is groundbreaking. It's a treatment that fulfills a big unmet need in cosmetic procedures," said New York oculoplastic surgeon Tabasum Mir, MD. "I have been using the Renuvion technology on patients in my practice and I've seen the transformative results firsthand. With the new clearance for Facial Renewal, this opens a whole new treatment option for patients to achieve the youthful appearance they're seeking."
"We are very pleased to receive FDA clearance with a specific clinical indication that enables Apyx Medical to market and sell our Renuvion Technology to physicians and patients for use in dermal resurfacing procedures," said Charlie Goodwin, President and Chief Executive Officer. "Facial Renewal with Renuvion offers patients a refreshed and more youthful look without having the unnatural 'pulled' appearance often associated with a facelift."
Note: Content may be edited for style and length.
Source
